GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD

25th April 2018 Uncategorised 0

US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.

More: GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
Source: News